Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.
Epistemonikos ID: ef8d1a742ac88fd0cca312226daed4a54525141f
First added on: Apr 29, 2020